Manufacturing

  1. The Future Of Cell And Organ Transplantation In Treating T1D With Dr. Camillo Ricordi 10/10/2023

    Explore the biggest and most troubling challenges facing the treatment of Type 1 Diabetes (T1D) and the future of cell and organ transplantation in treating T1D as well as the latest innovations in biopreservation.

  2. Planning For Manufacturing Capacity With Kite Pharma's Will Junker 9/26/2022

    Will Junker, Head of Manufacturing Quality at Kite Pharma, talks to Cell & Gene: The Podcast listeners about the challenges associated with capacity planning, whether to partner with a CDMO, and why it's important to prioritize inventory over time-to-market. We also discuss why developing a better understanding of the vector manufacturing process is critical to bringing continuous and secure supply to market.

  3. Dr. Bruce Levine on ISCT and the Future of CAR-T 5/23/2024

    In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and more.

  4. In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg 9/26/2023

    Discuss the evolution of allogeneic, in vivo CAR-T cell therapeutics, recent progress in lentiviral vector manufacturing, and The Colorado Laboratory and Innovation Manufacturing Building.

  5. The Near-Term Future Of Exosome Science With Capricor Therapeutics' Dr. Linda Marbán 4/12/2023

    Dr. Linda Marbán, Ph.D., CEO of Capricor Therapeutics, a clinical-stage biotech focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases, joins Cell & Gene: The Podcast's Erin Harris to discuss the current state and the near-term future of exosomes. Marbán discusses Capricor’s exosome program and the company’s proprietary allogeneic cardiosphere-derived cells (CDCs) and engineered exosomes. She also covers the company's HOPE clinical trial series' progress to treat Duchenne muscular dystrophy (DMD).

  6. TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou 5/10/2023

    Parviz Shamlou, Vice President and Executive Director at Thomas Jefferson University joins Cell & Gene: The Podcast to talk to Host Erin Harris about Jefferson Institute for Bioprocessing (JIB), the full-service development and training organization specializing in biopharmaceuticals and biologics. Shamlou explains how JIB will move forward cell and gene therapies as well as JIB’s partnership with NIBRT (National Institute for Bioprocessing Research & Training), and much more.

  7. Computational Biology's Role In Gene Therapy With Kriya Therapeutics' Dr. Shankar Ramaswamy 4/26/2023

    Shankar Ramaswamy, M.D., CEO & Co-Founder, Kriya Therapeutics joins Cell & Gene: The Podcast's Erin Harris for a discussion on the evolving role computational biology plays in gene therapy development. They also discuss the company's lessons learned from building its own North Carolina-based in-house manufacturing facility as well as Ramaswamy's insight on the future of gene therapy.

  8. The Future Of CAR-T With Bristol Myers Squibb's Lynelle Hoch 8/25/2023

    Check out a discussion on the near-term future of CAR-T, along with a deep dive into various innovations and patient access progress being made in both solid tumors and hematologic malignancies.

  9. Hospital Systems & Complex Therapies With University Of Pennsylvania Health System's Kevin Mahoney 8/20/2021

    On this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings to advanced therapies as well as how the Health System stays patient-focused at all costs.

  10. An Interview with Dr. Peter Marks 1/5/2023

    Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with Cell & Gene: The Podcast host Erin Harris to discuss the most anticipated areas of innovation in clinical development, and he offers recommendations to companies in their engagement with the FDA in order to make manufacturing more streamlined and cost effective. Dr. Marks also provides advice to listeners about how and when to engage with CBER, and much more.